Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Intravenous Single-Dose, Parallel, Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX13 and YERVOY® (US-, EU-, and CN-Sourced) in Healthy Chinese Male Subjects

NCT06159101 is registered in ClinicalTrials.gov with Shanghai Henlius Biotech as lead sponsor.

NCT NCT06159101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06159101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Intravenous Single-Dose, Parallel, Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX13 and YERVOY® (US-, EU-, and CN-Sourced) in Healthy Chinese Male Subjects
Lead sponsor
Shanghai Henlius Biotech
Phase
Phase 1
Overall status
Unknown status
Start date
November 28, 2023
Completion date
May 28, 2024
Enrollment
304 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy male volunteers